NEW YORK, March 1, 2005 (PRIMEZONE) -- David Lieberman, CEO of Advanced Plant Pharmaceuticals, Inc., (OTCBB:APPI) announced today the appointment of Dr. Mechael Kanovsky as President of Mazal Plant Pharmaceuticals Inc. to assist in the development of its three intended pharmaceutical formulas targeted for the treatment of high cholesterol, leukemia and Alzheimer's disease.
Dr. Mechael Kanovsky earned his PhD in Molecular Biology at Mount Sinai Medical School in New York and conducted cancer research initially in academia at the State University of New York (SUNY Downstate). Dr. Kanovsky moved into the biotech industry continuing his research on cancer and gene therapy at Gene Vector Technologies (Israel) and Marantech, Inc. (USA).
Dr Kanovsky, President of Mazal Plant Pharmaceuticals, stated that he was pleased to be joining Mazal Plant Pharmaceuticals. My initial goal is to focus on the Clinical IND/ NDA development of Mazal's cholesterol drug formula into a targeted cholesterol /HDL and triglyceride drug.
As previously announced, APPI owns 7,000,000 shares of common stock of Mazal and, as a result, is the majority shareholder. In addition, APPI will receive a royalty from Mazal on the three pharmaceutical formulas sold by APPI to Mazal Plant Pharmaceuticals.
Mazal's initial plans are to apply for an Investigational New Drug from the FDA and to pursue Phase II clinical trials for its cholesterol drug, MAHDL.
APPI continues to pursue sales of its nutritional product, Lo-Chol, targeted for the nutritional cholesterol market and Sinusol, an OTC homeopathic drug, for the treatment of sinus and allergy ailments.
About Advanced Plant Pharmaceuticals, Inc.
Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of whole plant-based products. The company has a composition-oriented patent for a proprietary process of utilizing whole plants to safely manufacture all-natural nutritional supplements. For more information, visit the Company's Corporate website: http://www.advancedplantpharm.com
About Mazal Pharmaceuticals, Inc.
Mazal Pharmaceuticals is focused on becoming an Industry leader in the treatment of Cholesterol /HDL and Triglyceride Treatment. Mazal Plant Pharmaceuticals is an innovator of whole plant pharmaceuticals drugs focused on the utilization of whole plants in the development of healthier pharmaceutical drugs for the treatment of human diseases.
Corporate website: www.mazal.cc
Forward-Looking Statements
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.